439239-90-4 | Lasmiditan

Availability
Typically In Stock

Description

• Catalog Number: AG20819
• Chemical Name: Lasmiditan
• CAS Number: 439239-90-4
• Molecular Formula: C19H18F3N3O2
• Molecular Weight: 377.3603
• MDL Number: MFCD18633238
• SMILES: CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F

Computed Properties

• Complexity: 530
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 2.8

Upstream Synthesis Route

2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide is a versatile compound widely utilized in chemical synthesis for its unique properties. This compound is specifically valuable in the field of medicinal chemistry due to its ability to selectively target and modify certain biological molecules. In organic synthesis, it serves as a valuable building block for creating complex molecules with specific functionalities. Its trifluoromethyl and pyridine moieties offer opportunities for strategic derivatization, making it a valuable tool for designing novel compounds with desired pharmacological activities. Furthermore, the presence of a piperidine moiety enhances its potential for interactions with biological targets, further expanding its utility in drug discovery and development processes.

Literature

• Emerging treatment for chronic migraine and refractory chronic migraine.

  Expert opinion on emerging drugs 20120901

• The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.

  The journal of headache and pain 20120601

• Defining and refining 5-HT receptor targets for migraine.

  The Lancet. Neurology 20120501

• Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.

  The Lancet. Neurology 20120501

• Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.

  Cephalalgia : an international journal of headache 20110701

• Treatment of migraine: update on new therapies.

  Current opinion in neurology 20110601

• Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.

  Cephalalgia : an international journal of headache 20101001

• Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.

  Cephalalgia : an international journal of headache 20101001

• Molecule of the month. Lasmiditan hydrochloride.

  Drug news & perspectives 20100901